A practical reference on gastric juice protein: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-18. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
The regular formation of alpha-sheet by unfolded proteins inevitably involves many L amino acid residues readily adopting the alphaL conformation, which appears at first sight to go against textbook chemistry, which is that, of the 20 amino acids, it is glycine that strongly favours this conformation. The conundrum is resolved by realizing that the alphaL region comprises two overlapping areas, here called γL and αL, which should be considered separately. It turns out that, while the γL conformation is adopted, almost exclusively, by glycine, the αL conformation of alpha-sheet is more commonly, or about as commonly, adopted by any of 15 L-amino acids compared to glycine, the exceptions being proline, threonine, valine and isoleucine, which are rare at this conformation. Hence, of the 20 amino acids, 16 readily adopt the αL conformation.
Elena Galoppini, Italian chemist and professor at Rutgers University–Newark whose research focuses on the development of redox- and photo-active molecules to modify surfaces. Juliet Gerrard, New Zealand chemist and Prime Minister's Chief Science Advisor in the administration of Jacinda Ardern. Clare Grey, British chemist pioneering the use of nuclear magnetic resonance spectroscopy to study battery technology. Awarded the Körber European Science Prize in 2021. Professor at the University of Cambridge. Paula T. Hammond, American chemical engineer focusing on macromolecular design and synthesis of materials for drug delivery systems, particularly in relation to cancer, immunology, and immunotherapy. Professor at MIT. Jeanne Hardy, American biophysicist and chemical biologist. Known for her work in the design of allosteric binding sites and control elements into human proteases. Professor at the University of Massachusetts. Geraldine Harriman, American Organic Chemist. Developed Firsocostat. Chief Scientific Officer and co-founder of HotSpot. Rachel Haurwitz, American biochemist and structural biologist. Her work regards CRISPR based technologies, she is a cofounder of Caribou Biosciences, a genome editing and cell therapy development company. Kim Eunkyoung, South Korean materials chemist known for her work in electrochromic (EC) materials design Katja Loos, German polymer chemist working on the design, synthesis, and characterisation of novel and sustainable polymeric materials and macromolecules. Chair of the board of the Zernike Institute for Advanced Materials.
Nine months earlier, he figured out that Starman's staff had imparted cosmic energy into him that was slowly healing his body. He therefore formed an alliance with the JSA's old enemy Ultra-Humanite and the surviving Dragon King to dig up his body and revive him. His plan was to transplant the Ultra-Humanite's brain into Starman's body to be his puppet that he would use to manipulate Stargirl and her JSA and become president as a mouthpiece for Icicle to enact his policies, since Starman was a beloved hero everyone admired, and the Dragon King's brain into the Ultra-Humanite's albino gorilla body for the former to "defeat" as Starman alongside Jordan's son. Christopher James Baker as Henry King Sr. / Brainwave (season 1; guest season 2):A member of the ISA with psionic abilities, the father of Henry King Jr. and a successful neurosurgeon at Blue Valley Medical Center. Baker stated that Henry King Sr. was the "mask" of Brainwave, as opposed to the other way around, believing Brainwave "is the true being". Amy Smart as Barbara Whitmore: Courtney's mother and Pat Dugan's wife who strives to balance her work and home life. After her marriage to Pat, she initially serves as a surrogate mother to her stepson Mike and also to Courtney's JSA teammates after discovering Pat and Courtney's secrets. Luke Wilson as Pat Dugan / S.T.R.I.P.E.:Courtney's stepfather, the former sidekick to Starman, and a mechanic who owns a repair garage where he stores a 15-foot robotic vehicle of his own creation made from spare car parts.
Sources: en.wikipedia.org
==== Places ==== In 2012, Doillon signed her first recording deal for three albums with Barclay (Universal Music France). Her first EP I.C.U came out in June and was produced by Étienne Daho and mixed by Philippe Zdar from the band Cassius. Doillon's first album was recorded in France over a 15 day period in the Studio La Seine with French musicians François Poggio, Marcello Guliani, Alexis Anérilles and Philippe Entressangle. Her debut album Places reached number three on the French charts. It also reached number one on Canadian iTunes, number two on French iTunes and was released through Verve in the US and decca in the UK. The artwork for the cover was done by Inez and Vinoodh. Doillon was on the cover of influential magazines Magic, Telerama and Les Inrockuptibles. The first single, "I.C.U", was followed by a video directed by Antoine Carlier, reconstituting her wanderings through Paris. Then came "Questions and Answers" directed by Gaetan Chataigner while Doillon was on tour and "Devil or Angel" directed by Christophe Acker in Scotland. In October 2012, Doillon started her first tour at French rock club La Flèche d'Or and played France, Belgium, Germany, Switzerland, Canada and England. This tour also played at Paris's Le Trianon venue. On 8 February 2013, during the Victoires de la musique ceremony (French equivalent of the Grammy's) at the Zenith of Paris, she was awarded Best Female Performer of the Year, competing alongside prestigious artists such as Françoise Hardy and Celine Dion. It was the first time a newcomer English-speaking performer won in that category.
== Target == Phrixotoxin-1 and -2 bind to A-type, transient, voltage-gated potassium channels, near the S3 and S4 segments, where they negatively affect transmembrane movement of the voltage sensing domain in response to depolarizing voltages. They bind preferentially to the closed or inactivated state of Kv4.2 and Kv4.3 channels(Chagot 2004). Phrixotoxin-3 (PaurTx3) inhibits several voltage gated sodium channel subtypes (Nav1.1/SCN1A, Nav1.2/SCN2A, Nav1.4/SCN4A, Nav1.5/SCN5A, and Nav1.8/SCN10A) (Bosmans 2006).
=== Necrotizing fasciitis === A study has found botox effective against necrotizing fasciitis caused by S. pyogenes in mice. Its mechanism of action is by blocking CGRP receptor of nerve cells, which trigger intense pain and activate CGRP cascade, which prevents the immune system attacks to control the pathogen. Botox blocks the CGRP cascade of nerve cells.
==== Primary mesenchyme ==== Primary mesenchyme is the first embryonic mesenchymal tissue to emerge, and it is produced from EMT in epiblast cells. In the epiblast, it is induced by the primitive streak through Wnt signaling, and produces endoderm and mesoderm from a transitory tissue called mesendoderm during the process of gastrulation. The formation of primary mesenchyme depends on the expression of WNT3. Other deficiencies in signaling pathways, such as in Nodal (a TGF-beta protein), will lead to defective mesoderm formation. The tissue layers formed from the primitive streak invaginate together into the embryo and the induced mesenchymal stem cells will ingress and form the mesoderm. Mesodermal tissue will continue to differentiate and/or migrate throughout the embryo to ultimately form most connective tissue layers of the body.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.